<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">107125</article-id><article-id pub-id-type="doi">10.17816/1028-9984-2021-26-2-49-56</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic value of quantitative assessment of macrophage content (CD68+) in the peritumoral zone of clear cell renal cell carcinoma</article-title><trans-title-group xml:lang="ru"><trans-title>Прогностическое значение количественной оценки содержания макрофагов (CD68+) в перитуморозной зоне светлоклеточного рака почки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9097-6733</contrib-id><contrib-id contrib-id-type="spin">2375-1427</contrib-id><name-alternatives><name xml:lang="en"><surname>Bobrov</surname><given-names>Igor P.</given-names></name><name xml:lang="ru"><surname>Бобров</surname><given-names>Игорь Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>ig.bobrov2010@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1080-5294</contrib-id><contrib-id contrib-id-type="spin">1161-8387</contrib-id><name-alternatives><name xml:lang="en"><surname>Lazarev</surname><given-names>Alexander F.</given-names></name><name xml:lang="ru"><surname>Лазарев</surname><given-names>Александр Федорович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>lazarev@arzs.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7292-4996</contrib-id><contrib-id contrib-id-type="spin">3773-8785</contrib-id><name-alternatives><name xml:lang="en"><surname>Cherdantseva</surname><given-names>Tatyana M.</given-names></name><name xml:lang="ru"><surname>Черданцева</surname><given-names>Татьяна Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>д.м.н., доцент</p></bio><email>cherdan.morf@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9889-9517</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimachev</surname><given-names>Ilya V.</given-names></name><name xml:lang="ru"><surname>Климачев</surname><given-names>Илья Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>pathologist</p></bio><bio xml:lang="ru"><p>врач-патологоанатом</p></bio><email>k0222@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1586-252X</contrib-id><contrib-id contrib-id-type="spin">8120-3059</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimachev</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>Климачев Владимир Васильевич</surname><given-names>Владимир Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathology_agmu@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3256-6706</contrib-id><name-alternatives><name xml:lang="en"><surname>Myadelets</surname><given-names>Mikhail N.</given-names></name><name xml:lang="ru"><surname>Мяделец</surname><given-names>Михаил Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), pathologist</p></bio><bio xml:lang="ru"><p>к.м.н., врач-патологоанатом</p></bio><email>pathology_agmu@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2477-4687</contrib-id><contrib-id contrib-id-type="spin">7516-0963</contrib-id><name-alternatives><name xml:lang="en"><surname>Lepilov</surname><given-names>Alexander V.</given-names></name><name xml:lang="ru"><surname>Лепилов</surname><given-names>Александр Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>lepilov@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7677-4622</contrib-id><contrib-id contrib-id-type="spin">2804-0011</contrib-id><name-alternatives><name xml:lang="en"><surname>Dolgatov</surname><given-names>Andrey Yu.</given-names></name><name xml:lang="ru"><surname>Долгатов</surname><given-names>Андрей Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>adolgatov@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0094-4656</contrib-id><name-alternatives><name xml:lang="en"><surname>Korsikov</surname><given-names>Nikolay A.</given-names></name><name xml:lang="ru"><surname>Корсиков</surname><given-names>Николай Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikkor94knaagmu@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6678-4472</contrib-id><name-alternatives><name xml:lang="en"><surname>Dolgatova</surname><given-names>Elena S.</given-names></name><name xml:lang="ru"><surname>Долгатова</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>esdol82@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2614-8690</contrib-id><contrib-id contrib-id-type="spin">3310-1175</contrib-id><name-alternatives><name xml:lang="en"><surname>Lushnikova</surname><given-names>Elena L.</given-names></name><name xml:lang="ru"><surname>Лушникова</surname><given-names>Елена Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathol@inbox.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9614-592X</contrib-id><contrib-id contrib-id-type="spin">3630-9977</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakarev</surname><given-names>Maxim A.</given-names></name><name xml:lang="ru"><surname>Бакарев</surname><given-names>Максим Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathol@inbox.ru</email><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Altai State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Алтайский государственный медицинский университет»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Altay State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Алтайский государственный медицинский университет»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Ryazan State Medical University</institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Рязанский государственный медицинский университет имени академика И.П. Павлова»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Institute of Molecular Pathology and Pathomorphology</institution></aff><aff><institution xml:lang="ru">Институт молекулярной патологии и патоморфологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2021</year></pub-date><volume>26</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>49</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2022-05-05"><day>05</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-23"><day>23</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Bobrov I.P., Lazarev A.F., Cherdantseva T.M., Klimachev I.V., Klimachev V.V., Myadelets M.N., Lepilov A.V., Dolgatov A.Y., Korsikov N.A., Dolgatova E.S., Lushnikova E.L., Bakarev M.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Бобров И.П., Лазарев А.Ф., Черданцева Т.М., Климачев И.В., Климачев Владимир Васильевич В.В., Мяделец М.Н., Лепилов А.В., Долгатов А.Д., Корсиков Н.А., Долгатова Е.С., Лушникова Е.Л., Бакарев М.А.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Bobrov I.P., Lazarev A.F., Cherdantseva T.M., Klimachev I.V., Klimachev V.V., Myadelets M.N., Lepilov A.V., Dolgatov A.Y., Korsikov N.A., Dolgatova E.S., Lushnikova E.L., Bakarev M.A.</copyright-holder><copyright-holder xml:lang="ru">Бобров И.П., Лазарев А.Ф., Черданцева Т.М., Климачев И.В., Климачев Владимир Васильевич В.В., Мяделец М.Н., Лепилов А.В., Долгатов А.Д., Корсиков Н.А., Долгатова Е.С., Лушникова Е.Л., Бакарев М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-04-15"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/107125">https://rjonco.com/1028-9984/article/view/107125</self-uri><abstract xml:lang="en"><p><bold><italic>AIM:</italic></bold> To quantitatively analyze the macrophage distribution density (MF) of the peritumoral zone (PZ) of clear cell renal cell carcinoma (CCRCC) and determine the relationship of MF distribution density in PZ with clinical and morphological prognostic variables and postoperative survival of patients.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold> The study included 52 patients with CCRCC, who had an average age of 56.7±0.8 years. Using monoclonal mouse antibodies for CD68 (clone PG-M1, DAKO), using an immunohistochemical method, macrophages were identified in the paraffin sections. The average amount of MF in the PZ was determined in three fields of view at ×400 magnification. For the PZ, the tissue was taken directly adjacent to the tumor to the conditionally unchanged kidney tissue.</p> <p><bold><italic>RESULTS:</italic></bold> The correlation analysis revealed that the density of the MF distribution in the CCRCC was interrelated with the stage of the disease (r=0.66; <italic>p</italic>=0.0001), size of the tumor node (r=0.52; <italic>p</italic>=0.0001), degree of anaplasia according to Fuhrman (r=0.80; <italic>p</italic>=0.0001), presence of metastases (r=0.62; 0.0001), and postoperative survival of patients (r=0.53; <italic>p</italic>=0.0001). However, there were no correlations with the gender (r=0.007; <italic>p</italic>=0.62) and age of the patients (r=0.03; <italic>p</italic>=0.83). With the number of MF in the PP &lt;8.8, the cumulative proportion of survivors by the five-year term was 0.70 (70%). Moreover, when the number of MF in the PZ was ≥8.8, none of the patients lived to the five-year term, the cumulative proportion of survivors was 0 (log-rank-test, <italic>p</italic>=0.000001).</p> <p><bold><italic>CONCLUSION:</italic></bold> The density of MF distribution in PZ is interrelated with significant clinical and morphological parameters of CCRCC and is a predictor of the prognosis of five-year postoperative survival of patients. Thus, quantitative estimation of the number of MF in the PZ can be used in predicting the course of CCRCC along with the traditional classical forecasting factors.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Цель.</italic></bold> Количественный анализ плотности распределения макрофагов (МФ) в перитуморозной зоне (ПЗ) светлоклеточного рака почки (СРП) и определение взаимосвязи плотности распределения МФ в ПЗ с клинико-морфологическими факторами прогноза и послеоперационной выживаемостью больных.</p> <p><bold><italic>Материалы</italic> <italic>и</italic> <italic>методы.</italic></bold> В исследование было включено 52 пациента с СРП, средний возраст больных составлял 56,7±0,8 лет. Макрофаги выявляли в парафиновых срезах иммуногистохимическим методом с помощью моноклональных мышиных антител к CD68 (клон PG-M1, DAKO). Высчитывали среднее количество МФ в ПЗ в 3 полях зрения при увеличении микроскопа х 400 (за ПЗ принимали ткань непосредственно прилежащую к опухоли до условно неизменённой ткани почки).</p> <p><bold><italic>Результаты.</italic></bold> При корреляционном анализе выявлено, что плотность распределения МФ в ПЗ СРП была взаимо- связана: со стадией заболевания (r=0,66; <italic>p</italic>=0,0001); размером опухолевого узла (r=0,52; <italic>p</italic>=0,0001); степенью анаплазии по Fuhrman (r=0,80; <italic>p</italic>=0,0001); наличием метастазов (r=0,62; <italic>p</italic>=0,0001) и послеоперационной выживаемостью больных (r=0,53; <italic>p</italic><italic>=</italic>0,0001). Не было обнаружено корреляционных взаимосвязей с полом (r=0,007; <italic>p</italic>=0,62) и возрастом пациентов (r=0,03; <italic>p</italic>=0,83). При числе МФ в ПЗ &lt;8,8 кумулятивная доля выживших к 5-летнему сроку составляла – 0,70 (70%), а когда число МФ в ПЗ было ≥8,8, то до 5-летнего срока не дожил ни один из пациентов, кумулятивная доля выживших при этом составила 0 (log-rank-test, <italic>p</italic>=0,000001).</p> <p><bold><italic>Выводы.</italic></bold> Плотность распределения МФ в ПЗ была взаимосвязана с важными клинико-морфологическими параметрами СРП и являлась предиктором прогноза 5-летней послеоперационной выживаемости больных. Количественная оценка числа МФ в ПЗ может быть использована при прогнозировании течения СРП в качестве дополнительного фактора, в совокупности с традиционными классическими факторами прогноза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>clear cell renal cell carcinoma</kwd><kwd>peritumoral zone</kwd><kwd>macrophages</kwd><kwd>prognosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>светлоклеточный рак почки</kwd><kwd>перитуморозная зона</kwd><kwd>макрофаги</kwd><kwd>прогноз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Messex JK, Byrd CJ, Liou G-Y. Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development. Cells. 2020;9(4):919. doi: 10.3390/cells9040919</mixed-citation><mixed-citation xml:lang="ru">Messex J.K., Byrd C.J., Liou G.Y. Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development // Cells. 2020. Vol. 9, N 4. P. doi: 10.3390/cells9040919</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Lazarev AF, Bobrov IP, Cherdantseva TM, et al. Mast cells and tumor growth. Siberian Juornal of oncology. 2011;46(4):59–63.</mixed-citation><mixed-citation xml:lang="ru">Лазарев А.Ф., Бобров И.П., Черданцева Т.М., и др. Тучные клетки и опухолевый рост // Сибирский онкологический журнал. 2011. Т. 46, № 4. С. 59–63.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Bobrov IP, Cherdantseva TM, Dolgatova ES, et al. Predictive Value of Quantitative Assessment B-Lymphocytes in the Peritumorous Zone in Renal Cell Carcinoma. Modern Problems of Science and Education. 2021;2:160–160. (In Russ). doi: 10.17513/spno.30739</mixed-citation><mixed-citation xml:lang="ru">Бобров И.П., Черданцева Т.М., Долгатова Е.С., и др. Прогностическое значение количественной оценки В-лимфоцитов в перитуморозной зоне рака почки // Современные проблемы науки и образования. 2021. № 2. С. 172.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Cherdantseva TM, Bobrov IP, Avdalyan AM, et al. Mast cells in renal cancer: morphological correlations and prognosis. Bulletin of Experimental Biology and Medicine. 2017;163(6):768–773. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Черданцева Т.М., Бобров И.П., Авдалян А.М., и др. Тучные клетки при раке почки: клинико-морфологические взаимосвязи и прогноз // Бюллетень экспериментальной биологии и медицины. 2017. Т. 163, № 6. С. 768–773.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Kazarcev AV, Cherdanceva TM, Bobrov IP, et al. Intratumoral Stromal Mast Cells in Renal Cell Carcinoma: Clinical and Morphological Comparisons. Russian Journal of Oncology. 2017;22(1):21–24. (In Russ). doi: 10.18821/1028-9984-2017-22-1-21-24</mixed-citation><mixed-citation xml:lang="ru">Казарцев А.В., Черданцева Т.М., Бобров И.П., и др. Интратуморальные стромальные тучные клетки при почечно-клеточном раке: клинико-морфологические сопоставления // Российский онкологический журнал. 2017. Т. 22, № 1. С. 21–25.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009;123(2):97–102. doi: 10.1016/j.imlet.2009.02.011</mixed-citation><mixed-citation xml:lang="ru">Siveen K.S., Kuttan G. Role of macrophages in tumour progression // Immunol Lett. 2009. Vol. 123, N 2. P. 97–102. doi: 10.1016/j.imlet.2009.02.011</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Sumitomo R, Hirai T, Fujita M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer. Exp Ther Med. 2019;18(6):4490–4498. doi: 10.3892/etm.2019.8068</mixed-citation><mixed-citation xml:lang="ru">Sumitomo R., Hirai T., Fujita M., et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer // Exp Ther Med. 2019. Vol. 18, N 6. P. 4490–4498. doi: 10.3892/etm.2019.8068</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Song H, Wang T, Tian L, et al. Macrophages on the Peritoneum are involved in Gastric Cancer Peritoneal Metastasis. J Cancer. 2019;10(22):5377–5387. doi: 10.7150/jca.31787</mixed-citation><mixed-citation xml:lang="ru">Song H., Wang T., Tian L., et al. Macrophages on the Peritoneum are involved in Gastric Cancer Peritoneal Metastasis // J Cancer. 2019. Vol. 10, N 22. P. 5377–5387. doi: 10.7150/jca.31787</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Choi J, Gyamfi J, Jang H, Koo JS. The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 2018;33(2):133–145. doi: 10.14670/HH-11-916</mixed-citation><mixed-citation xml:lang="ru">Choi J., Gyamfi J., Jang H., Koo J.S. The role of tumor-associated macrophage in breast cancer biology // Histol Histopathol. 2018. Vol. 33, N 2. P. 133–145. doi: 10.14670/HH-11-916</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Waniczek D, Lorenc Z, Snietura M, et al. Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017;65(5):445–454. doi: 10.1007/s00005-017-0463-9</mixed-citation><mixed-citation xml:lang="ru">Waniczek D., Lorenc Z., Snietura M., et al. Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer // Arch Immunol Ther Exp (Warsz). 2017. Vol. 65, N 5. P. 445–454. doi: 10.1007/s00005-017-0463-9</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Sugimura K, Miyata H, Tanaka K, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol. 2015;111(6):752–759. doi: 10.1002/jso.23881</mixed-citation><mixed-citation xml:lang="ru">Sugimura K., Miyata H., Tanaka K., et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer // J Surg Oncol. 2015. Vol. 111, N 6. P. 752–759. doi: 10.1002/jso.23881</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Hamada I, Kato M, Yamasaki T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002;22(6C):4281–4284.</mixed-citation><mixed-citation xml:lang="ru">Hamada I., Kato M., Yamasaki T., et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma // Anticancer Res. 2002. Vol. 22, N 6C. P. 4281–4284.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2013;62(12):1757–1768. doi: 10.1007/s00262-013-1487-6</mixed-citation><mixed-citation xml:lang="ru">Santoni M., Massari F., Amantini C., et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma // Cancer Immunol Immunother. 2013. Vol. 62, N 12. P. 1757–1768. doi: 10.1007/s00262-013-1487-6</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Toge H, Inagaki T, Kojimoto Y, et al. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol. 2009;16(10):801–807. doi: 10.1111/j.1442-2042.2009.02377.x</mixed-citation><mixed-citation xml:lang="ru">Toge H., Inagaki T., Kojimoto Y., et al. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages // Int J Urol. 2009. Vol. 16, N 10. P. 801–807. doi: 10.1111/j.1442-2042.2009.02377.x</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Hutterer GC, Pichler M, Chromecki TF, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology. 2013;63(3):309–315. doi: 10.1111/his.12163</mixed-citation><mixed-citation xml:lang="ru">Hutterer G.C., Pichler M., Chromecki T.F., et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma // Histopathology. 2013. Vol. 63, N 3. P. 309–315. doi: 10.1111/his.12163</mixed-citation></citation-alternatives></ref></ref-list></back></article>
